Newsfeeds - Spark Newswire

1 minute read

Analyst Ratings

HC Wainwright & Co. Maintains Buy Rating for Aadi Bioscience, Lowers Price Target To $48

Today, 3:59 AM

HC Wainwright & Co. has decided to maintain its Buy rating of Aadi Bioscience (NASDAQ:AADI) and lower its price target from $49.00 to $48.00. Shares of Aadi Bioscience are trading down 4.87% over the last 24 hours, at $16.62 per share.

AADI

1 minute read

HC Wainwright & Co. Maintains Buy on Aadi Bioscience, Lowers Price Target to $48

By Benzinga Newsdesk

Today, 3:59 AM

HC Wainwright & Co. analyst Robert Burns maintains Aadi Bioscience (NASDAQ:AADI) with a Buy and lowers the price target from $49 to $48.

AADI

2 minute read

Aadi Bio Reports First Patient Dosed In Its PRECISION Phase 2 Trial Of nab-Sirolimus In Patients with Solid Tumors Harboring Pathogenic Inactivating Alterations in TSC1 and TSC2 Genes

By Benzinga Newsdesk

Today, 3:59 AM

FDA grants Fast Track designation for nab-sirolimus for the treatment of adult and adolescent patients with Tuberous Sclerosis Complex 1 and 2 (“TSC1” and “TSC2”) alterations LOS ANGELES, March

AADI

2 minute read

Aadi Bioscience Announces U.S. Commercial Launch And Availability Of FYARRO For The Treatment Of Adult Patients With Locally Advanced Unresectable Or Metastatic Malignant PEComa

By Benzinga Newsdesk

Today, 3:59 AM

Aadi Bioscience, Inc. ("Aadi") (NASDAQ:AADI), a biopharmaceutical company focusing on precision therapies for genetically-defined cancers with alterations in mTOR pathway genes, today announced the launch and

AADI

10 minute read

Benzinga’s Top Ratings Upgrades, Downgrades For January 11, 2022

By Benzinga Insights

Today, 3:59 AM

2 minute read

The Week Ahead In Biotech (Nov. 28-Dec. 4): FDA Decisions For VBI Vaccines, BeyondSpring, CTI Biopharma And Merck Take The Spotlight In A Light Calendar Week

By Shanthi Rexaline

Today, 3:59 AM

Biotech stocks advanced in the week ending Nov. 26, as a late-week surge on the back of news about a new COVID-19 variant, named Omicron, helped mitigate the losses notched earlier in the holiday-shortened week.

AADI

1 minute read

Aadi Bioscience Shares Rally On FDA Approval For Its First Product For Rare Form Cancer

By Vandana Singh

Today, 3:59 AM

The FDA has approved Aadi Bioscience Inc's (NASDAQ:

AADI

3 minute read

The Week Ahead In Biotech (Nov. 21-Nov. 27): Takeda, Aadi, Fennec FDA Decisions, Earnings In The Spotlight In Holiday-Shortened Week

By Shanthi Rexaline

Today, 3:59 AM

Biotech stocks showed a lack of direction in the week ending Nov. 19 before finishing modestly higher. Stocks did not have much meaningful catalysts to react to amid the winding down of the reporting season and ahead of the holiday week.

AADI

6 minute read

76 Biggest Movers From Yesterday

By Lisa Levin

Today, 3:59 AM

Gainers Expensify, Inc. (NASDAQ: EXFY) jumped 52.1% to settle at $41.06 on Wednesday after the company priced its IPO at $27 per share.

AADI

5 minute read

Attention Biotech Investors: Mark Your Calendar For November PDUFA Dates

By Shanthi Rexaline

Today, 3:59 AM

The loaded Prescription Drug User Fee Act (PDUFA) calendar for October produced mixed outcomes. PDUFA dates are key binary events for biotech stocks that can move the needle in a big way. These are the dates by which the Food and Drug Administration is required to announce its decision regarding approvability/non-approvability of drugs.

AADI